Exclusives

A study has been completed in Salamanca, Spain, to evaluate the effectiveness of a standardized foot care protocol in individuals with diabetes in primary care. Outcome measures include identification of those at risk and having a DFU. No...

Imbed announced a Technology Breakthrough designation for PelashieldAM with Premier through its Kiindo pediatric performance group and collaborative. PelashieldAM is indicated for use primarily in burn wounds and is manufactured in multiple...

Perceptive Solutions announced the launch of WoundZoom Pro, an advanced application that has non-contact three-dimensional wound measurement technology and an intuitive workflow application that can all be accessed on a clinician's smart...

RTI announced that it has completed its previously announced acquisition of Cook Biotech Incorporated. The combined entity offers a differentiated portfolio of allograft and xenograft biomaterials at scale. No financial details were...

A 75-patient study will observe the efficacy and safety of EPIFIX dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable DFUs or VLUs with the primary outcome of wound closure at 4, 8, and 12 weeks and adverse...

Aroa reported that enrollment in AROA’s multi-center Symphony randomized control trial for DFUs approximately doubled during Q323, with a total of 86 participants enrolled to date (n=120)

Coloplast announced US launch of Biatain Silicone Fit, a new silicone foam dressing with 3DFit Technology designed for pressure injury prevention and wound management. The Company aims to grow its presence within the US foam dressings segment...

Rion announced initiation of Phase 2A clinical study to assess the safety and efficacy of its Purified Exosome Product (PEP) for management of DFUs. A positive outcome of the pivotal study will be followed by the submission of a Biologics...